Non-hla restricted t cell receptors and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
Claims53
A recombinant T cell receptor (TCR) comprising an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC peptide and/or a native or modified TRBC peptide.
An immunoresponsive cell comprising a recombinant TCR that comprises an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC peptide and/or a native or modified TRBC peptide.
A method for producing an antigen-specific immunoresponsive cell, the method comprising introducing into an immunoresponsive cell a nucleic acid molecule encoding a recombinant TCR comprising an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC polypeptide and/or a native or modified TRBC polypeptide.
Dependencies are inferred from the claim text.